Vanda Pharmaceuticals (VNDA) News Today $4.70 +0.08 (+1.73%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$4.74 +0.04 (+0.85%) As of 07:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VNDA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia ...4 hours ago | finanznachrichten.deVanda Pharmaceuticals Announces Participation at September 2025 Investor ConferencesAugust 28 at 5:23 PM | prnewswire.comVanda Pharmaceuticals stock rises after FDA orphan drug designationAugust 28 at 8:23 AM | za.investing.comVanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia VeraAugust 28 at 7:00 AM | prnewswire.comVanda Pharmaceuticals treatment of polycythemia vera granted orphan designationAugust 27 at 2:11 AM | msn.comVanda Pharmaceuticals' (VNDA) Buy Rating Reaffirmed at HC WainwrightAugust 23, 2025 | marketbeat.comVanda seeks FDA Commissioner review of Hetlioz generic rulingAugust 22, 2025 | msn.comVanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®August 21, 2025 | prnewswire.comVanda Pharmaceuticals shares rise after court overturns FDA denialAugust 18, 2025 | za.investing.comVanda Pharmaceuticals Shares Climb After Court Reverses FDA DecisionAugust 18, 2025 | msn.comVanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-MarkAugust 18, 2025 | msn.comIn a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag DisorderAugust 18, 2025 | prnewswire.comHC Wainwright Issues Pessimistic Outlook for VNDA EarningsAugust 16, 2025 | marketbeat.comHC Wainwright Has Bearish Forecast for VNDA Q4 EarningsAugust 15, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Has $4.27 Million Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)August 15, 2025 | marketbeat.comVanda Pharmaceuticals (NASDAQ:VNDA) Posts Earnings Results, Misses Expectations By $0.12 EPSAugust 3, 2025 | marketbeat.comVanda Pharmaceuticals (NASDAQ:VNDA) Downgraded by Wall Street Zen to Strong SellAugust 3, 2025 | marketbeat.comShort Interest in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Increases By 2,603.2%August 2, 2025 | marketbeat.com190,536 Shares in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Acquired by Universal Beteiligungs und Servicegesellschaft mbHAugust 2, 2025 | marketbeat.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q2 2025 Earnings Call TranscriptAugust 1, 2025 | msn.comVanda (VNDA) Q2 Revenue Rises 4%August 1, 2025 | fool.comVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports Second Quarter 2025 Financial ResultsAugust 1, 2025 | finanznachrichten.deVanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call TranscriptJuly 31, 2025 | seekingalpha.comVanda Pharmaceuticals Q2 2025 Earnings: EPS Misses at -$0.46, Revenue Falls Short at $52.6 MillionJuly 31, 2025 | gurufocus.comVanda Pharmaceuticals misses top-line and bottom-line estimates; reaffirms FY25 outlookJuly 31, 2025 | seekingalpha.comVanda Pharmaceuticals Reports Second Quarter 2025 Financial ResultsJuly 31, 2025 | prnewswire.comGSA Capital Partners LLP Acquires 121,797 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)July 31, 2025 | marketbeat.comVanda Pharmaceuticals Q2 Earnings PreviewJuly 30, 2025 | msn.comMonaco Asset Management SAM Lowers Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)July 30, 2025 | marketbeat.comVanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025 | VNDA ...July 23, 2025 | gurufocus.comVanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025July 23, 2025 | prnewswire.comVanda Pharmaceuticals (NASDAQ:VNDA) Stock Price Crosses Above 200 Day Moving Average - Here's What HappenedJuly 10, 2025 | marketbeat.comVNDA - Vanda Pharmaceuticals Inc Executives - MorningstarJuly 9, 2025 | morningstar.comMVanda Pharmaceuticals (NASDAQ:VNDA) Stock Crosses Above 200-Day Moving Average - Should You Sell?July 2, 2025 | marketbeat.comVNDA - Vanda Pharmaceuticals Inc Chart - MorningstarJune 24, 2025 | morningstar.comMInsider Selling: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Sells 7,000 Shares of StockJune 18, 2025 | insidertrades.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Sells $32,130.00 in StockJune 17, 2025 | marketbeat.comInsider Sell: Stephen Mitchell Sells 7,000 Shares of Vanda Pharmaceuticals Inc (VNDA)June 16, 2025 | gurufocus.comVanda Pharmaceuticals (NASDAQ:VNDA) Upgraded to Hold at Wall Street ZenJune 14, 2025 | marketbeat.comBrokers Issue Forecasts for VNDA FY2026 EarningsJune 11, 2025 | marketbeat.comVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2SJune 10, 2025 | finanznachrichten.deVanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2SJune 10, 2025 | prnewswire.comJane Street Group LLC Decreases Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)June 8, 2025 | marketbeat.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Purchased by Two Sigma Investments LPJune 7, 2025 | marketbeat.comMillennium Management LLC Buys 269,183 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)June 1, 2025 | marketbeat.comVanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual MeetingMay 27, 2025 | prnewswire.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Sold by Lazard Asset Management LLCMay 26, 2025 | marketbeat.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Sold by D. E. Shaw & Co. Inc.May 25, 2025 | marketbeat.comInsider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Acquires 10,000 Shares of StockMay 22, 2025 | insidertrades.comKrensavage Asset Management LLC Cuts Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)May 22, 2025 | marketbeat.com Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VNDA Media Mentions By Week VNDA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VNDA News Sentiment▼0.301.03▲Average Medical News Sentiment VNDA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VNDA Articles This Week▼74▲VNDA Articles Average Week Get the Latest News and Ratings for VNDA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Vanda Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies OPKO Health News Today Geron News Today Rigel Pharmaceuticals News Today Zenas BioPharma News Today Myriad Genetics News Today Verastem News Today Emergent Biosolutions News Today Lexicon Pharmaceuticals News Today XOMA Royalty News Today Crescent Biopharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VNDA) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access